Neoplasms

Immune System Diseases

All Conditions

Blood and Lymph Conditions

Rare Diseases

Plasmacytoma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Immunoproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Durvalumab

Atezolizumab

Antineoplastic Agents, Immunological

Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.

durvalumab 1500mg administered intravenously every 28 days, for a total of six doses

concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting

Radiation therapy

Alexander Lesokhin, MD

This study is being done to evaluate whether the combination of immune therapy and radiation therapy to plasmacytoma that can stimulate the immune system to attack and eliminate the abnormal cells in the bone marrow and perhaps delay or prevent the cancer from worsening. This study will evaluate whether the immune system responds to the combination of radiation with immunotherapy. It is possible that that the combination of immune therapy and radiation may not make any difference in whether or not the patient will develop multiple myeloma in the future.

This is an open-label, single center, single-arm pilot study of checkpoint blockade therapy (anti-PD-L1) plus radiation.

A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

A Pilot Study to Evaluate for the Abscopal Effect of Durvalumab (Anti-PD-L1) in Combination With Definitive Radiation Therapy in Solitary Bone Plasmacytoma With Limited Clonal Bone Marrow Plasmacytosis

Disease assessments are made according to IMWG criteria including criteria for minimal residual disease

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma	NCT03196401	Solitary Bone P...	Durvalumab Radiation thera...	18 Years -	Memorial Sloan Kettering Cancer Center
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma	NCT03196401	Solitary Bone P...	Durvalumab Radiation thera...	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for solitary bone plasmacytoma